Scotland

R&D

Big promises, hard work: What 2026 will demand from pharma

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

From pilots to patients: Why the UK must rethink NHS innovat...

At PharmaTech Integrates in Glasgow, speakers from government, academia, the NHS, and pharma sought to define the sector’s path forward.

Digital

How do we unlock the potential of digital health?

‘Digital health’ has been heralded for some time as a new era in patient outcomes, offering increased access to care, enhanced clinical decision-making, and greater efficiency in healthcare

R&D

Why Scotland is well-positioned to lead in advanced therapie...

The global health burden of complex diseases such as severe lung, liver, and vascular disease is huge, and growing by the second.

News

Genomic testing 'should be offered to all cancer patients in...

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targ

News

NICE verdict on Trodelvy threatens unequal access to drug in...

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.